TY - JOUR
T1 - C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases
T2 - Relative findings and response to therapy
AU - Yu, Evan Y.
AU - Muzi, Mark
AU - Hackenbracht, Joy A.
AU - Rezvani, Brian B.
AU - Link, Jeanne M.
AU - Montgomery, Robert Bruce
AU - Higano, Celestia S.
AU - Eary, Janet F.
AU - Mankoff, David A.
PY - 2011/3
Y1 - 2011/3
N2 - Purpose of the Report: This study tested the feasibility of C11-acetate (acetate) positron emission tomography (PET) imaging to assess response to therapy in men with bone metastatic prostate cancer and compared results for disease detection and response evaluation with F-18 fluorodeoxyglucose (FDG) PET. Materials and Methods Men with >3 prostate cancer bone metastases identified by Tc-99m methylene diphosphonate (MDP) bone scintigraphy and/or computed tomography were enrolled in a prospective study of serial acetate and FDG PET imaging. Patients were imaged before and 6 to 12 weeks after initial androgen deprivation therapy for new metastatic prostate cancer or first-line chemotherapy with docetaxel for castration-resistant prostate cancer. Qualitative assessment and changes in the tumor:normal uptake ratio were used to assess response by both acetate and FDG PET. In addition, the detection of bone metastases pretherapy was compared for acetate and FDG PET. Results: A total of 8 patients with documented bone metastases were imaged, of which 6 were imaged both pre- and post-therapy. Acetate PET detected bone metastases in all 8 patients, whereas FDG PET detected lesions in 6 of the 7 imaged patients. Acetate PET generally detected more metastases with a higher tumor:normal uptake ratio. Qualitative and quantitative assessments of post-treatment response correlated with composite clinical designations of response, stable disease, or progression in 6 of 6 and 5 of 6 by acetate and 4 of 5 and 3 of 5 by FDG PET, respectively. Conclusion: In this pilot study, results indicate that acetate PET holds promise for response assessment of prostate cancer bone metastases and is complementary to FDG PET in bone metastasis detection.
AB - Purpose of the Report: This study tested the feasibility of C11-acetate (acetate) positron emission tomography (PET) imaging to assess response to therapy in men with bone metastatic prostate cancer and compared results for disease detection and response evaluation with F-18 fluorodeoxyglucose (FDG) PET. Materials and Methods Men with >3 prostate cancer bone metastases identified by Tc-99m methylene diphosphonate (MDP) bone scintigraphy and/or computed tomography were enrolled in a prospective study of serial acetate and FDG PET imaging. Patients were imaged before and 6 to 12 weeks after initial androgen deprivation therapy for new metastatic prostate cancer or first-line chemotherapy with docetaxel for castration-resistant prostate cancer. Qualitative assessment and changes in the tumor:normal uptake ratio were used to assess response by both acetate and FDG PET. In addition, the detection of bone metastases pretherapy was compared for acetate and FDG PET. Results: A total of 8 patients with documented bone metastases were imaged, of which 6 were imaged both pre- and post-therapy. Acetate PET detected bone metastases in all 8 patients, whereas FDG PET detected lesions in 6 of the 7 imaged patients. Acetate PET generally detected more metastases with a higher tumor:normal uptake ratio. Qualitative and quantitative assessments of post-treatment response correlated with composite clinical designations of response, stable disease, or progression in 6 of 6 and 5 of 6 by acetate and 4 of 5 and 3 of 5 by FDG PET, respectively. Conclusion: In this pilot study, results indicate that acetate PET holds promise for response assessment of prostate cancer bone metastases and is complementary to FDG PET in bone metastasis detection.
KW - C11-acetate (acetate)
KW - F-18 fluorodeoxyglucose (FDG)
KW - bone metastases
KW - positron emission tomography (PET)
KW - prostate cancer
KW - response
UR - http://www.scopus.com/inward/record.url?scp=79951563645&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79951563645&partnerID=8YFLogxK
U2 - 10.1097/RLU.0b013e318208f140
DO - 10.1097/RLU.0b013e318208f140
M3 - Article
C2 - 21285676
AN - SCOPUS:79951563645
VL - 36
SP - 192
EP - 198
JO - Clinical Nuclear Medicine
JF - Clinical Nuclear Medicine
SN - 0363-9762
IS - 3
ER -